Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06517888 · ClinicalTrials.gov registry record · Phase 1
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
A Phase 1 study of Vestibular Schwannoma, sponsored by Akouos.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 4
- Study locations
NCT06517888 is a Phase 1 study of Vestibular Schwannoma that is actively recruiting participants, run by Akouos. The registered enrollment target is 27 participants, below the 49-participant average among 7 other Vestibular Schwannoma trials with a reported enrollment target (45% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06517888, a Phase 1 study of Vestibular Schwannoma, is actively recruiting participants, sponsored by Akouos.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 4
- Study locations
Study Summary
This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Conditions Studied
Interventions
- COMBINATION_PRODUCT AAVAnc80-antiVEGF via Akouos Delivery Device
Study Locations (4)
Maryland
- Johns Hopkins Hospital - Baltimore
Minnesota
- Mayo Clinic - Rochester
Tennessee
- Vanderbilt Bill Wilkerson Center - Nashville
Texas
- University of Texas Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2025-01-17 |
| Est. Completion | 2029-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06517888
The ClinicalTrials.gov registry entry for NCT06517888 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 49-participant average among 7 other Vestibular Schwannoma trials with a reported enrollment target (45% lower). The listed sponsor is Akouos, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vestibular Schwannoma appearing as the primary indexed condition, and to 1 intervention - of which AAVAnc80-antiVEGF via Akouos Delivery Device is the first listed.
NCT06517888 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Maryland, Minnesota, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06517888 about?
NCT06517888 is a clinical study titled "Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma". This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
What is the current status of trial NCT06517888?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2025-01-17. Estimated completion is 2029-08.
What conditions does trial NCT06517888 study?
This clinical trial studies the following conditions: Vestibular Schwannoma.
What interventions are being tested in trial NCT06517888?
The interventions under investigation include: AAVAnc80-antiVEGF via Akouos Delivery Device (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT06517888?
This trial is sponsored by Akouos, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06517888 being conducted?
This trial has 4 study locations across Maryland, Minnesota, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vestibular Schwannoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
StableEyes With Active Neurofeedback
RECRUITING · NA
-
CI Following VS Removal or Labyrinthectomy
RECRUITING · NA
-
Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients with Vestibular Schwannomas
RECRUITING · NA
-
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
ACTIVE NOT RECRUITING · Phase 2
-
Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Aspirin in Patients With Vestibular Schwannoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.